Related Experiment Video
Updated: May 28, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
Understanding and Managing Immunoglobulin A Nephropathy
Kate K Romano1, Michael R Brodeur1, Darren W Grabe1
1Albany College of Pharmacy and Health Sciences, Albany, New York.
Purpose:
Immunoglobulin A nephropathy (IgAN) is the most common pattern of primary glomerular disease worldwide and remains a leading cause of chronic kidney disease and kidney failure. The intent of the current article is to review the 2025 Clinical Practice Guideline from Kidney Disease: Improving Global Outcomes (KDIGO) for the management of IgAN and summarize updated evidence-based diagnostic and therapeutic strategies.
Method:
Current literature, clinical evidence, and guideline recommendations on the management of IgAN are reviewed.
Results:
The updated guideline emphasizes early biopsy-confirmed diagnosis, proteinuria-guided risk assessment, and optimized supportive care, including strict blood pressure control and kidney protective therapies. In addition, newer disease-specific treatments that target pathogenic forms of IgA and IgA-immune complexes should be used simultaneously.
Conclusion:
The 2025 KDIGO guideline advances IgAN management through an interdisciplinary, multi-targeted, evidence-based approach aimed at reducing proteinuria, preserving kidney function, and improving long-term renal outcomes.
Related Concept Videos
Nephrotic Syndrome III : Nursing Management
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease III: Interprofessional Care
Nephrotic Syndrome I : Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease IV: Nursing Management
